The last of the main maker of the main antibiotic components closes the largest local factory

Stay in view of the free updates

Simply subscribe to Pharmaceutical Myft Digest – it is delivered directly to your inbox.

The last component of Europe for some antibiotics closes its largest local factory and turns some production to China, which deals with Brussels efforts to reduce drug dependence on Asia.

Xellia Pharmaceuticals said that it can survive only against the Chinese competition by transferring many of its products to its factory there.

Half of the active pharmaceutical components in Xellia (APIS) recently List of the European Union for Critical Medicines And the World Health Organization list for basic drugs.

The Danish company told employees on Tuesday that it would close its factory in Copenhagen, which led to the loss of 500 jobs. Currently, it will retain a more cost -effective European process in Budapest.

CEO Michael Kushir said that unless the government -funded health systems are ready to pay more against public medicines, and more companies in European Union The factories will move.

“We are discussing a lot about retail. I think it is easier to make sure that what we have in Europe remains in Europe,” he told the Financial Times in an interview.

The xllia -made medicine components include vanquicin, which is necessary to produce antibiotics that can treat severe infections such as blood rot, which resist other drugs.

About 80 for all applications used in the European Union, which already comes from China. With the absence of tense health systems that are not willing to increase the prices of medicines, Kocher suggested that subsidies are the only way to ensure that the European Union maintains some control of these important components.

“Otherwise, only 80 percent of the application programming facades will not come from China. It will be close to 100 percent soon,” he said.

Kushir stressed that the Western demand for vancomicin hydrochloride can be fulfilled from Budapest if the conditions of the market improved.

In March, the European Commission revealed proposals that can be included in the critical medicine law to try to address the consequences offered by the Covid-19s, when the two countries rise from drugs, protective clothes and equipment such as ventilation devices.

These proposals aim to increase the production of the European Union to more than 200 drugs, of antibiotics such as penicillin and erythromycin, to pain relievers such as laidocaine and morphine.

The measures discussed include allowing the countries to join wholesaler purchases, and the benefit of European Union products in purchasing operations. But Kushir said the policies were very shy and took a long time to implement them.

“The costs are increasing, you are trying to transfer these costs to your customer, then your customers decide that the costs are very high and increase the arrow from China,” he said. “We are seeking … commitment to supporting continuous operations.”

Heavy research companies have warned that the low prices paid by European health systems are leading efforts to discover new medicines to the United States and China.

The CEO of Novartis and Sannovi wrote to the committee last month to An invitation to high prices. They also pointed out that the American customs tariff was pushing companies to invest in North America. However, Xellia said it has no plans to do the same.

Xellia, owned by Novo Nordisk, sells the Danish pharmaceutical power to more than 500 companies in 80 countries. It will take a decade to slowly transfer production from its factory in Copenhagen elsewhere.

Kokhir said that the European Union should put a greater value on its “saving life” products that treat meningitis and other deadly conditions. “Without our product portfolio, we will face a big challenge. Covid will be a small problem compared,” he said.